drugset
drugset / Trial / NCT04216771

Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

NCT04216771 ↗

Phase 2/3 Unknown 320 enrolled Fujian Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates Idarubicin (IDA) in combination with the intermediate-dose cytarabine, compared with intermediate-dose cytarabine alone, as a consolidation treatment for elderly AML in first remission.

Timeline

Start
2020-01
Primary completion
2022-05
Completion
2024-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 1.5 g Intravenous
Subject Idarubicin Small molecule 10 mg/m2 Intravenous

Indications

acute myeloid leukemia